ASCO: Seagen’s top-selling drug under threat as Bristol Myers’ Opdivo beats Adcetris in lymphoma – FiercePharma

by

  1. ASCO: Seagen’s top-selling drug under threat as Bristol Myers’ Opdivo beats Adcetris in lymphoma FiercePharma
  2. Trial demonstrates one-year progression-free survival in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma Medical Xpress
  3. New Ovarian Cancer Drug Extends Survival in Resistant Disease Medpage Today
  4. Mirvetuximab Soravtansine Results from MIRASOL Deemed Practice-Changing for Frα+ Platinum-Resistant Ovarian Cancer Targeted Oncology
  5. Benefits of Neoadjuvant Nivolumab/Chemo Elucidated in NSCLC Exploratory Analysis OncLive

Read original article here

Leave a Comment